Bio NC
Filter News
Found 17,095 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
5/8/2023
Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, May 11, 2023.
-
Dentsply Sirona to Participate in Upcoming Investor Conferences
5/8/2023
DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced its participation at upcoming conferences.
-
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate
5/8/2023
Milestone Pharmaceuticals Inc. today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Monday, May 22, 2023 at 8:00 a.m. ET.
-
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
5/8/2023
Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th.
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc.
-
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023
5/5/2023
Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2023, on Friday, May 12, 2023.
-
Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez
5/5/2023
It is with deep sadness that Aerami Therapeutics (“Aerami”) today announces that our dear friend, fierce patient advocate, dedicated mentor, and CEO, Lisa Yañez suddenly passed away on Tuesday, May 2, 2023.
-
Quest Diagnostics Extends Alzheimer's Disease Portfolio with New AI-Powered Test Service from uMETHOD Health
5/4/2023
Quest Diagnostics today announced nationwide availability of the RestoreU ™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline.
-
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
5/4/2023
Chimerix today reported financial results for the first quarter ended March 31, 2023 and provided an operational update.
-
Humacyte’s Human Acellular Vessel™ (HAV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma
5/4/2023
Humacyte, Inc. (Nasdaq: HUMA) has been recently granted the U.S. Food and Drug Administration’s (FDA’s) Regenerative Medicine Advanced Therapy (RMAT) designation for its Human Acellular Vessel (HAV) for urgent arterial repair following extremity vascular trauma.
-
ProKidney to Present at the BofA Securities Health Care Conference 2023
5/4/2023
ProKidney Corp. announced that Dr. Tim Bertram, Chief Executive Officer, will present at the BofA Securities Health Care Conference 2023 in Las Vegas, NV on Tuesday, May 9, 2023, at 4:20 PM PDT.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023
5/4/2023
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 34,000 shares, and restricted stock units covering an aggregate of 23,800 shares, of BioCryst common stock.
-
Congruence Therapeutics to Present at Multiple Investor Conferences in May 2023
5/4/2023
Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced that management will participate in the following investor conferences.
-
LABCORP TO WEBCAST ITS ANNUAL MEETING OF SHAREHOLDERS - May 4, 2023
5/4/2023
Labcorp today announced that its Annual Meeting of Shareholders will be webcast live on May 11 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website.
-
LABCORP AND JEFFERSON HEALTH ANNOUNCE STRATEGIC LABORATORY RELATIONSHIP
5/3/2023
Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey.
-
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
5/3/2023
United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter ended March 31, 2023.
-
Dentsply Sirona Reports First Quarter 2023 Results
5/3/2023
Dentsply Sirona Inc. announced its financial results for the first quarter of 2023.
-
EmergeOrtho--Triangle Region Welcomes Dr. Josh Hudgens, Expert in Shoulder Surgery
5/3/2023
EmergeOrtho—Triangle Region is pleased to announce the addition of Dr. Josh Hudgens to the expert orthopedic care team.
-
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
5/3/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the first quarter ended March 31, 2023.